Quanta Announces Dosing of First Patient in Phase 1/1b Clinical Trial of QTX3046, an Oral KRASᴳ¹²ᴰ-Selective Dual-State Allosteric Inhibitor, and Other Program Updates Quanta is advancing 2 clinical trials from its pipeline of KRAS G12D-focused drug candidates, as monotherapy and combination with EGFR inhibitors

Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates

Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.